ALMR Alamar Biosciences, Inc. Insider Trading

Illumina Innovation Fund II GP bought 235,294 shares of ALMR for $3,999,998 on debut trading day; now holds 507,076 shares post-transaction.

Illumina Innovation Fund II GP, a 10% owner, purchased 235,294 shares of Alamar Biosciences at $17.00, totaling $3,999,998, at the same price point that marked the stock's first two trading days. The fund's holding position grew by 86.6% relative to its pre-transaction stake of 271,782 shares, resulting in post-transaction holdings of 507,076 shares. This substantial accumulation by a major shareholder occurs in the immediate aftermath of the company's public listing and reflects a significant commitment of capital into the newly listed entity. The purchase timing—coinciding with the IPO window—combined with the meaningful increase in pro-rata ownership stake warrants attention from investors monitoring large shareholder positioning and capital deployment patterns in the biotech sector.

Director Naclerio buys 235,294 shares of ALMR at $17.00 for $3,999,998.00 in derivative conversion during recent IPO window.

Director Nicholas Naclerio purchased 235,294 shares at $17.00 for a total value of $3,999,998.00 on 2026-04-20, just two trading days after Alamar Biosciences listed publicly. The trade reflects a conversion of derivative securities rather than a discretionary open-market acquisition. The current market price of $22.00 represents a $5.00 premium to the conversion price, indicating the director's derivative position gained value between the strike and market execution. This conversion activity is a standard post-IPO event when restricted equity instruments vest or convert; it does not indicate the director's current cash position or forward-looking conviction about the stock. Investors should examine the Form 4 Table II derivative securities table (not yet populated in this database) to understand the full scope of Naclerio's unvested or remaining derivative holdings and their terms.